Optimi Health to Supply MDMA for Psychedelic Research at Tel Aviv University
March 26, 2024 07:30 ET
|
Optimi Health Corp.
Supply agreement marks Optimi’s first international shipment of research-grade active pharmaceutical ingredient (API) MDMA to Israel
Patent Allowance Granted for P-1 Molecule by US Patent and Trademark Office
March 20, 2024 10:20 ET
|
PharmAla Biotech
PharmAla Recieves Notice of Allowance of Patent on Novel MDMA-like Molecule with improved safety, therapeutic range
Cortexa Leads the World in First Supply of Psilocybin Under the TGA’s Authorized Prescriber Scheme
March 18, 2024 08:55 ET
|
PharmAla Biotech
PharmAla's 50:50 Joint Venture with Vitura Health Limited, Cortexa, announces it is first entity to supply Psilocybin into Authorized Prescriber Scheme
MAPS Provides Psychedelic Crisis Assessment and Intervention Training to Denver’s First Responders
March 11, 2024 11:50 ET
|
Multidisciplinary Association for Psychedelic Studies (MAPS)
MAPS uses its over 30 years of experience in the psychedelic space to offer a first-of-its-kind gold-standard training program.
PharmAla Announces Voting Results of Annual General and Special Meeting of Shareholders and Provides Corporate Update
March 08, 2024 16:15 ET
|
PharmAla Biotech
PharmAla provides corporate update following AGM
atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01
March 04, 2024 08:00 ET
|
atai Life Sciences
The Phase 1b trial of VLS-01 investigates the pharmacokinetics, pharmacodynamics, safety and tolerability of atai’s proprietary, optimized oral transmucosal formulation of DMTVLS-01 is being developed...
atai Life Sciences to Participate in the Upcoming TD Cowen 44th Annual Health Care Conference
February 28, 2024 17:00 ET
|
atai Life Sciences
NEW YORK and BERLIN, Feb. 28, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health...
Optimi Announces Closing of First Tranche of Non-Brokered Private Placement
February 28, 2024 07:30 ET
|
Optimi Health Corp.
VANCOUVER, British Columbia, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a Health Canada licensed drug researcher and...
PharmAla named an Intellectual Property Ontario Client
February 22, 2024 08:55 ET
|
PharmAla Biotech
PharmAla recieves a non-dilutive grant from IP Ontario (IPON) to support its patent work in international markets.
PharmAla Data to be Published in ACS Chemical Neuroscience
February 20, 2024 08:55 ET
|
PharmAla Biotech
PharmAla's drug discovery data to be published in ACS Chemical Neuroscience; PharmAla presents data at ISRP Conference in New Orleans